A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study
- Tsai, M.-C.
- Chen, C.-H.
- Hung, C.-H.
- Lee, C.-M.
- Chiu, K.-W.
- Wang, J.-H.
- Lu, S.-N.
- Tseng, P.-L.
- Chang, K.-C.
- Yen, Y.-H.
- Hu, T.-H.
DOIAbstract
AbstractThere are limited data comparing the clinical outcomes between telbivudine and entecavir. We consecutively enrolled 115 telbivudine-naive and 115 entecavir-naive chronic hepatitis B patients, who were matched for age, sex, hepatitis B e antigen (HBeAg) status and cirrhosis, and treated for at least 2 years or less than 2 years but had developed resistance. Except for the rate of HBeAg seroconversion, which was similar, patients in the entecavir group had better clinical outcomes than those in the telbivudine group for alanine aminotransferase normalization (85.2% vs 78.4%, p <0.048), undetectable HBV DNA (96.5% vs 74.8%, p <0.001), and viral resistance (0.9% vs 21.7%, p <0.001) after 2 years of treatment, After applying roadmap or s...
Add to ORKG